Results 201 to 210 of about 7,268 (227)

Cellular, Structural Basis, and Recent Progress for Targeting Murine Double Minute X (MDMX) in Tumors.

Journal of Medicinal Chemistry
Murine double minute X (MDMX) is an oncoprotein that mainly has a negative regulatory effect on the tumor suppressor p53 to induce tumorigenesis. As MDMX is highly expressed in various types of tumor cells, targeting and inhibiting MDMX are becoming a ...
Qi-Kun Yin, Yue-Miao Hu, Zhiwen Dong, Jing Lu, Hong-Bo Wang   +4 more
semanticscholar   +1 more source

Abstract 5682: Micro RNA level changes in prostate cancer cells treated with MDMX and MDM2 inhibitors

Cancer Research
INTRODUCTION: Prostate Cancer (PCa) is the most common non-cutaneous cancer and the second leading cause of cancer death among men in the United States. Most of the PCa cases are diagnosed in men between the ages of 65-74.
Rojin Fatirkhorani, Ahmed Alsarrani, S. Jaganathan, Umamaheswari Natarajan, A. Rathinavelu   +4 more
semanticscholar   +1 more source

Selinexor Induces DLBCL Cell Senescence Mediated By USP1/MDMX/p53 Axis

Blood
Background: Despite the increasing number of treatment options available for Diffuse Large B-Cell Lymphoma (DLBCL), only about half of patients achieve long-term clinical benefits. Selinexor, the selective XPO1 inhibitor, received approval as single
Yidan Zhang, Xi-Yue Xu, Xian-Huo Wang, Hui-Lai Zhang   +3 more
semanticscholar   +1 more source

Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels

2014
No description ...
Susan Tudhope, Yan Zhao, Anita Wittner, Elaine Wilmore, Annalisa Bertoli, Santosh Adhikari, Suzannah Harnor, Fabio Del Bello, Alessandro Piergentili, John Lunec, Ian Hardcastle, Roger J. Griffin, Bernard Golding, Celine Cano, David Newell, Stephen Wedge   +15 more
openaire   +1 more source

Unlocking the Anticancer Potential of New Spirooxindoles via p53-MDM2/MDMX Dual Inhibition: In Vitro and In Silico Assessments.

Drug development research (Print)
Blocking the p53-MDM2 and/or p53-MDMX protein-protein interaction (PPI) by small-molecule inhibitors has been tracked as a potentially effective cancer treatment approach.
H. El-Zoheiry, Rehab F. Ahmed, Mahmoud S. Elkotamy, Hatem A. Abdel-Aziz, Ghada F. Elmasry   +4 more
semanticscholar   +1 more source

In Situ Study of p53, MDM2, and MDMX Protein Interaction in Living Cells Using Fluorescence Triple Correlation Spectroscopy.

Analytical Chemistry
The tumor suppressor protein p53 is a crucial transcription factor that regulates physiological processes, including apoptosis, cell cycle progression, DNA damage stress and repair, and programmed cell death. The activity of the intracellular p53 protein
Xin-Wei Lu, Kun Zang, Chao-Liang Diao, Chao-Qing Dong, Ji-Cun Ren   +4 more
semanticscholar   +1 more source

Mdm2 and MdmX Involvement in Human Cancer

2014
Discovered in 1987 and 1997 respectively, Mdm2 and MdmX represent two critical cellular regulators of the p53 tumor suppressor. This chapter reviews each from initial discovery to our current understanding of their deregulation in human cancer with a focus on how each regulator impacts p53 function. While p53 independent activities of Mdm2 and MdmX are
openaire   +2 more sources

A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies.

Clinical Cancer Research
PURPOSE ALRN-6924 is a stapled peptide that disrupts MDM2/MDMX-mediated inhibition of p53. We evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ALRN-6924 in children with advanced malignancies.
D. Shulman, Kieuhoa T. Vo, F. Balis, Holly Lindsay, Bradley Denardo, Andrew E. Place, Susan N. Chi, J. Kamihara, Allison F. O'Neill, A. Church, B. Crompton, Kelly S. Klega, Mohammad Tanhaemami, M. Armant, Y. Pikman, K. Stegmaier, Suzanne Ezrre, Jeffrey Czaplinski, Loren D. Walensky, D. Annis, K. Bhushan, Pei-Chi Kao, W. London, Steven G. Dubois   +23 more
semanticscholar   +1 more source

Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target

Leukemia, 2023
Yu-Hung Wang, Chien-Chin Lin, Kristian Gurashi, Bettina Wingelhofer, Fabio M. R. Amaral, Chi-Yuan Yao, Hsin-Ti Hsieh, Ming-Chih Liu, H. Hou, W. Chou, K. Batta, D. Wiseman, H. Tien   +12 more
semanticscholar   +1 more source

MdmX

2011
openaire   +1 more source